Brokerages Set DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Target Price at $13.54

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has been assigned a consensus rating of “Hold” from the fifteen analysts that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $13.5385.

Several equities research analysts have recently issued reports on XRAY shares. Barclays increased their target price on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an “underweight” rating in a research note on Monday, August 24th. Barrington Research set a $15.00 target price on shares of DENTSPLY SIRONA in a research note on Monday, August 10th. Weiss Ratings restated a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research report on Monday, August 3rd. BMO Capital Markets reissued a “market perform” rating and issued a $13.00 price objective on shares of DENTSPLY SIRONA in a report on Friday, August 7th. Finally, Piper Sandler increased their price objective on DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 29th.

Insider Buying and Selling at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director Brian McKeon acquired 10,000 shares of the stock in a transaction dated Friday, June 12th. The stock was acquired at an average price of $10.12 per share, with a total value of $101,200.00. Following the completion of the purchase, the director owned 10,000 shares in the company, valued at $101,200. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Brian Gladden bought 9,985 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were acquired at an average cost of $10.02 per share, for a total transaction of $100,049.70. Following the completion of the purchase, the director owned 61,849 shares in the company, valued at $619,726.98. This trade represents a 19.25% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 35,160 shares of company stock valued at $351,179 in the last three months. 0.46% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of XRAY. First Eagle Investment Management LLC raised its stake in DENTSPLY SIRONA by 3.2% during the 4th quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock worth $167,342,000 after acquiring an additional 458,744 shares in the last quarter. Paradigm Capital Management Inc. NY acquired a new position in DENTSPLY SIRONA in the second quarter valued at $39,775,000. Edmond DE Rothschild Holding S.A. acquired a new position in DENTSPLY SIRONA in the second quarter valued at $47,780,000. BlackRock Inc. purchased a new position in shares of DENTSPLY SIRONA during the second quarter worth about $283,405,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of DENTSPLY SIRONA during the second quarter worth about $16,408,000. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Stock Performance

Shares of XRAY stock opened at $10.99 on Wednesday. The stock has a market cap of $2.19 billion, a PE ratio of -4.00, a price-to-earnings-growth ratio of 1.45 and a beta of 0.84. The business has a 50-day simple moving average of $12.18 and a 200-day simple moving average of $11.64. The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 1.48. DENTSPLY SIRONA has a 52-week low of $9.40 and a 52-week high of $14.76.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, topping the consensus estimate of $0.35 by $0.17. The firm had revenue of $898.00 million for the quarter, compared to analyst estimates of $889.93 million. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%.DENTSPLY SIRONA’s revenue for the quarter was down 4.1% compared to the same quarter last year. During the same period last year, the company earned $0.52 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, equities analysts expect that DENTSPLY SIRONA will post 1.4 EPS for the current year.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.